In a UK diabetes model at the liraglutide 1.2 mg price benchmark, weekly exenatide had an ICER of £10,597/QALY versus insulin glargine.
In plain wordsIn a UK diabetes model using a liraglutide price benchmark, weekly exenatide cost more and provided more health benefits than insulin glargine.
- Peptide
- Exenatide (exendin-4)
- Outcome
- IncreaseBase-case cost utility
- Study
n: not reported in source
- Comparator
- insulin glargine
- Outcome group
- Cost-effectiveness · Whole body
Measurements
- ICER
- 10,597 GBP/QALY
- base case
Source sentences
At a price equivalent to liraglutide 1.2 mg, EQW was more effective and more costly than insulin glargine, with a base case ICER of £10,597 per quality-adjusted life-year (QALY) gained.
2 context sentences(design, population, supporting numbers)
The IMS CORE Diabetes Model was used to project clinical and economic outcomes for patients with type 2 diabetes treated with EQW or insulin glargine.
The analysis was conducted from the perspective of the UK National Health Service over a time horizon of 50 years with costs and outcomes discounted at 3.5%.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).